Table IV.
Association between clinicopathologic characteristics and disease free survival.
| Clinicopathological variables | Total | Hazard ratio (95% CI) | P-value |
|---|---|---|---|
| PKM2 expression (continuous) | 371 | 1.129 (1.023–1.247) | 0.016 |
| PKM2 expression (categorical, above or below median of 11.25) | 371 | 1.406 (1.044–1.895) | 0.025 |
| Sex (male vs. female) | 370 | 1.155 (0.842–1.583) | 0.372 |
| Diagnosis age (continuous) | 370 | 0.997 (0.985–1.009) | 0.625 |
| BMI (continuous) | 334 | 0.984 (0.958–1.010) | 0.220 |
| Creatinine (continuous) | 298 | 1.002 (0.987–1.017) | 0.819 |
| Fetoprotein (continuous, log2 converted) | 277 | 1.038 (1.001–1.077) | 0.047 |
| Albumin (continuous) | 295 | 1.009 (0.983–1.036) | 0.507 |
| Residual tumor (R0 vs. R1 or R2) | 364 | 1.763 (1.091–2.848) | 0.021 |
| Vascular tumor invasion (none vs. micro or macro) | 315 | 1.990 (1.407–2.814) | <0.001 |
| Adjacent hepatic tissue inflammation (none vs. mild or severe) | 234 | 0.833 (0.577–1.204) | 0.332 |
| Stage (I or II vs. III or IV) | 348 | 2.376 (1.712–3.298) | <0.001 |
| Grade (1 or 2 vs. 3 or 4) | 366 | 1.106 (0.811–1.507) | 0.525 |
CI, confidence interval; BMI, body mass index; PKM2, pyruvate kinase muscle isozyme M2.